When it comes to battling leukemia, especially in complex or relapsed cases, stem cell transplantation stands as a cornerstone of curative intent. At GoBroad, we understand the pivotal role of hematopoietic stem cell transplantation (HSCT) in transforming outcomes for patients with leukemia, and we take pride in offering a comprehensive, patient-centered approach to this advanced therapy. With a focus on precision, innovation, and compassionate care, we have established ourselves as a trusted provider of stem cell transplant for leukemia, combining decades of experience with cutting-edge technology to deliver hope where it’s needed most.

A Legacy of Expertise in Hematologic Care

At GoBroad, our journey in stem cell transplant for leukemia is rooted in a deep commitment to advancing treatments for blood cancers. Our medical centers, including Beijing GoBroad Boren Hospital, are equipped to handle all stages of HSCT, from initial evaluation to post-transplant recovery. We recognize that each patient’s needs are unique, which is why we offer a range of transplant options—including autologous, allogeneic, sibling-matched, unrelated donor, haploidentical, and cord blood transplants—to suit individual diagnoses and genetic profiles. Our team has successfully performed thousands of transplants for both adult and pediatric patients, including those as young as 1 month old and up to 72 years old, with success rates that align with international benchmarks. This breadth of experience allows us to approach even the most challenging cases with confidence, whether treating acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), or chronic forms of the disease.

Tailored Transplant Strategies for Optimal Outcomes

Central to our approach is the belief that no two leukemia cases are the same, and neither should their transplant plans be. We begin with thorough diagnostic evaluations, using advanced genetic sequencing, cytology, and flow cytometry to identify molecular markers and determine the most suitable transplant type. For example, patients with relapsed ALL may benefit from a haploidentical transplant when a fully matched donor is unavailable, while those with AML might undergo autologous transplant following chemotherapy remission. Our transplant team specializes in customizing pre-treatment regimens to minimize toxicity and maximize engraftment, incorporating targeted therapies or CAR-T cell therapy when appropriate—such as bridging CAR-T with HSCT for patients like VARELII, a Russian patient who achieved deep remission after a second transplant failed, highlighting our ability to combine modalities for complex cases. Post-transplant, we prioritize close monitoring for complications like graft-vs-host disease (GvHD) or infections, leveraging our expertise in immunotherapy and supportive care to ensure stable recovery.

A Multidisciplinary Team Committed to Your Journey

The success of stem cell transplant for leukemia relies on collaboration, and at GoBroad, our multidisciplinary team (MDT) brings together hematologists, transplant surgeons, oncologists, infectious disease specialists, and nurses to create a seamless care experience. Our experts, including Dr. Defeng ZHAO, who guided VARELII’s treatment, have decades of experience in managing the physical and emotional challenges of transplantation. We work closely with patients and families to explain each step, from donor matching to post-transplant lifestyle adjustments, ensuring informed decisions and emotional support. Our facilities feature specialized laminar flow wards to protect immunocompromised patients during recovery, paired with advanced imaging and laboratory services to monitor progress with precision. This integrated approach means patients receive not just medical treatment, but a network of support designed to enhance their quality of life throughout the process.

Innovative Research and Global Collaboration

As a research-oriented hospital group, we are constantly exploring ways to improve stem cell transplant for leukemia through clinical trials and international partnerships. We participate in studies evaluating new conditioning regimens, novel anti-infective strategies, and the integration of CAR-T therapy with HSCT to boost remission rates in refractory cases. Our collaboration with global institutions ensures we stay at the forefront of transplant innovations, such as using cord blood transplants for pediatric patients or refining haploidentical techniques to expand donor availability. These efforts not only benefit our patients but also contribute to global advancements in hematopoietic stem cell transplantation, solidifying our role as a leader in both clinical practice and research.

Conclusion

When facing leukemia, choosing a provider with proven expertise in stem cell transplantation can make all the difference. At GoBroad, we combine decades of experience, personalized treatment strategies, and a compassionate multidisciplinary team to guide you through every stage of your journey. Whether you’re considering transplant as a first-line curative option or seeking rescue therapy for relapsed disease, we are here to provide the expertise, innovation, and support you need. Trust in our commitment to delivering advanced, patient-centered care—because at GoBroad, your health and hope are our priority.